我国是世界糖尿病大国。2019 年国际糖尿病联盟(IDF)公布的数据显示,在全世界糖尿病患病人数最多的前 10 名国家中,中国排在第一位,中国糖尿病患病人数已达 1.16 亿[1]。2020 年 4 月,由滕卫平教授发布的中国最新糖尿病流行病学调查数据显示,中国糖尿病患病率已达 12.8%,糖尿病前期患病率为 35.2%[2]。
餐后高血糖定义及病理生理
餐后血糖控制
GLP-1RA 受到国内外指南推荐
GLP-1RA 分类及特点
参考文献:
1. 2019 年 IDF 全球糖尿病地图(第九版)
2. Prevalence of diabetes recorded in China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study [J]. British Medical Journal. 2020;28(4);369:m997.
3. Comparison of the Fasting and the 2-h Glucose Criteria for Diabetes in Different Asian Cohorts [J]. Diabetologia. 2000;43(12):1470-1475.
4. 中国 2 型糖尿病患者餐后高血糖管理专家共识 [J]. 中国糖尿病杂志. 2016;24(5):385-392.
5. Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults [J]. Diabetes Care. 2019;42(8):1539-1548.
6. Glucagon-like peptide 1 (GLP-1) [J]. Molecular Metabolism. 2019;30(12):72-130.
7. Drug Therapy in Obesity: A Review of Current and Emerging Treatments [J]. Diabetes Therapy. 2020;11(6):1199-1216.
8. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists [J]. Diabetes Obes Metab. 2016;18(4):317-332.
9. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials [J]. Can J Diabetes. 2020;44(1):68-77.
10. Cardiovascular outcome trials of glucose-lowering therapies [J]. Expert Rev Pharmacoecon Outcomes Res. 2020;20(3):237-249.
11. Differential Indication for SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients With Established Atherosclerotic Heart Disease or at Risk for Congestive Heart Failure [J]. Metabolism. 2020;104:154045.
12. GLP-1RAs in Type 2 Diabetes: Mechanisms That Underlie Cardiovascular Effects and Overview of Cardiovascular Outcome Data [J]. Cardiovasc Diabetol. 2018;17(1):157.
13. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J]. European Heart Journal. 2020;41(2):255-323.
14. Standards of Medical Care in Diabetes 2020 [J]. Diabetes Care. 2020 Jan;43(Suppl 1).
15. 中国 2 型糖尿病防治指南 (2017 年版) [J]. 中华糖尿病杂志. 2018;10(1):4-67.
16. 4.GLP-1 受体激动剂临床应用专家指导意见 [J]. 中国糖尿病杂志. 2018;26(5):353-361.